Cardiac Rhythm Management Devices Market is Expected to Amplify USD 29.9 Billion Value by 2028: Grand View Research Inc.

The second wave of coronavirus turns out deadly all across the world in 2021 than the first in 2020. Although, the vaccination drives are being conducted throughout the world adhering to the guidelines by WHO, the transmission of virus variants is adding more challenge. The cases of cardiac arrests have been mounting up in the elder patients with a high mortality rate driven by sudden cardiac arrests is one of the major concern associated with COVID infection.

An estimated 3.5 lac sudden cardiac arrest cases occur in the U.S. The research led by Penn revealed that there was decreased in stability for survival of cardiac patients during the pandemic. Mainly, this occurred due to the lack of CPR and fear of viral transmission. However, for infected patients, doctors recommend hands-only CPR (under safe conditions) which is a safe and effective way to help them during cardiac arrests. Even though there is a low risk of transmission.

Considering the severity cardiac rhythm management devices can be looked upon as a saviour in life threatening situations.

Simply put, the job of cardiac rhythm management device is to restore normal rhythm/heart functioning in cardiac patients. Cardiac rhythm management devices perform many functions such as bradycardia pacing, defibrillation, pacing for tachyarrhythmias and so on. Any of these implanted device (under supervision of physician) enables the patients to lead normal and active lives. Future projections for developing a leadless yet customized design will be highly innovative. Thus, we can say that the focus will shift from transvenous lead to leadless design in the coming years.

COVID-19 Impact Post-COVID Outlook
The COVID-19 impact has had a severe impact over cardiology, electrophysiology, and cardiac rhythm management device systems. The cardiac rhythm management devices market is likely to witness some upcoming trends. Medical companies are proactively providing essential supplies despite the existing challenges.
The quality care in patients is likely to get altered amid the line of procedure for COVID affected patients. Abbott Laboratories have partnered with support communities to fight against COVID. By collaborating with the communities, they aim to provide access to medicines, diagnostics, nutrition without any disruption
There was sudden spike in the  cardiovascular cases affected by coronavirus resulting in the growing need for HRCT, electrocardiogram, and other diagnostic tests. Home monitoring will gain traction as consumers are adopting SMART wearable gadgets following RPM (Remote Patient Monitoring) techniques for patients.
Briefing the impact COVID-19 has made on the cardiac rhythm management devices market

Summing up:

As we move forward in 2021 with vaccines against COVID-19, it is likely that we might witness a decline trend in fresh cases all across the world. Hopefully, this will reduce the burden on healthcare systems. On the other hand, patients in a post-COVID phase should still continue with health precautions as advised by their doctors and physicians. This is likely to encourage the use of pacemakers, defibrillators, and implantable devices to monitor heart health in the coming time as remote monitoring and homecare for cardiac patients will be a major norm.

(Visited 1 times, 1 visits today)

Comments

comments

You may also like...